Multivariate analysis of clinicopathological parameters in DLBCLs treated with R-CHOP
| . | OS . | PFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| B symptoms | 1.47 | 1.04-2.09 | .0310 | 1.45 | 1.03-2.03 | .0314 |
| Tumor size, ≥7.5 cm | 1.22 | 0.87-1.71 | .2467 | 1.21 | 0.86-1.69 | .2708 |
| IPI risk, >2 | 2.38 | 1.67-3.38 | <.0001 | 2.22 | 1.59-3.11 | <.0001 |
| COO classification, ABC | 1.17 | 0.79-1.72 | .4329 | 1.18 | 0.82-1.71 | .3750 |
| TP53 mutation | 1.72 | 1.17-2.52 | .0057 | 1.63 | 1.12-2.37 | .0105 |
| MYC/BCL2 coexpression | 2.52 | 1.73-3.67 | <.0001 | 2.45 | 1.71-3.51 | <.0001 |
| . | OS . | PFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| B symptoms | 1.47 | 1.04-2.09 | .0310 | 1.45 | 1.03-2.03 | .0314 |
| Tumor size, ≥7.5 cm | 1.22 | 0.87-1.71 | .2467 | 1.21 | 0.86-1.69 | .2708 |
| IPI risk, >2 | 2.38 | 1.67-3.38 | <.0001 | 2.22 | 1.59-3.11 | <.0001 |
| COO classification, ABC | 1.17 | 0.79-1.72 | .4329 | 1.18 | 0.82-1.71 | .3750 |
| TP53 mutation | 1.72 | 1.17-2.52 | .0057 | 1.63 | 1.12-2.37 | .0105 |
| MYC/BCL2 coexpression | 2.52 | 1.73-3.67 | <.0001 | 2.45 | 1.71-3.51 | <.0001 |
CI, confidence interval; HR, hazard ratio.